Susan Solymoss, MD
Primary Axis:
Health Outcomes
Email:
Email contact form Research Focus:
Research interest focuses on management of venous thromboembolism. Evaluation of novel anticoagulants in the prevention of venous thromboembolism, and novel anticoagulants in the treatment of venous thromboembolism are the main foci of numerous multicenter prospective clinical trials in which I participate. Laboratory evaluation of coagulation parameters in patients at risk of venous thromboembolism or atherosclerosis for risk prediction/stratification is the primary focus in the laboratory.Venous thrombosis, treatment, prevention, novel anticoagulants, hypercoagulable states
Keywords:
Venous thrombosis, treatment, prevention, novel anticoagulants, hypercoagulable states
Location:
Montreal General Hospital Publications:
Kearon C, Ginsberg JS, Kovacs M, Anderson DR, Wells P, Julian J, Mackinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn S, Kassis J, Rodger M, Hambleton J, Gent M. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. New England Journal of Medicine 2003; 349: 631-639.
Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. Journal of Clinical Oncology 2003; 21: 4194-4199.
Huynh T, Theroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001; 103: 33069-33074.
